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Abstract
Background: Breast cancer (BC) causes more deaths than any other cancer among women in Catalonia. Early
detection has contributed to the observed decline in BC mortality. However, there is debate on the optimal
screening strategy. We performed an economic evaluation of 20 screening strategies taking into account the cost
over time of screening and subsequent medical costs, including diagnostic confirmation, initial treatment, follow-
up and advanced care.
Methods: We used a probabilistic model to estimate the effect and costs over time of each scenario. The effect
was measured as years of life (YL), quality-adjusted life years (QALY), and lives extended (LE). Costs of screening
and treatment were obtained from the Early Detection Program and hospital databases of the IMAS-Hospital del
Mar in Barcelona. The incremental cost-effectiveness ratio (ICER) was used to compare the relative costs and
outcomes of different scenarios.
Results: Strategies that start at ages 40 or 45 and end at 69 predominate when the effect is measured as YL or
QALYs. Biennial strategies 50-69, 45-69 or annual 45-69, 40-69 and 40-74 were selected as cost-effective for both
effect measures (YL or QALYs). The ICER increases considerably when moving from biennial to annual scenarios.
Moving from no screening to biennial 50-69 years represented an ICER of 4,469€ per QALY.
Conclusions: A reduced number of screening strategies have been selected for consideration by researchers,
decision makers and policy planners. Mathematical models are useful to assess the impact and costs of BC
screening in a specific geographical area.
Background
In Catalonia (Spain), as in the majority of Western
countries, breast cancer (BC) is the cancer with the
highest incidence among women (almost 1/3 of all
malignant neoplasms). BC causes more deaths than any
other cancer (18% of the cancer deaths in Catalan
women in the 1998-2002 period) [1]. Early detection
and adjuvant treatments have contributed to the
observed decline in BC mortality since the 1990s. How-
ever, there is debate over the optimal screening strategy,
including frequency and starting and ending ages.
The economic cost of BC is also important. In the
USA, BC drugs are the second biggest category of all
pharmaceutical sales, growing at double the overall
market [2]. Early detection of BC produces a stage shift
in the direction of more favorable prognosis relative to
the distribution of stages seen with symptomatic detec-
tion and may result in treatment savings. Nevertheless,
early detection also affects the costs of initial treatment
and follow-up. A new hypothesis has been proposed in
recent studies, that improving the stage at diagnosis by
early detection is unlikely to result in large treatment
savings. The savings in treatment and palliative care for
advanced BC may be counterbalanced by the high costs
of more aggressive initial treatment and longer follow-
up [3,4]. Since population based screening programs are
funded by community resources, an economic evalua-
tion that considers the long-term consequences of dif-
ferent scenarios both on outcomes (benefits and harms)
and costs should be performed.
Economic evaluation is based on a comprehensive
assessment of effects and costs. Cost-effectiveness
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obtaining an additional unit of health outcome, compar-
ing the costs and outcomes of different health interven-
tions or strategies within the same intervention. Costs
are valued in monetary units and effectiveness is valued
in years of life, mortality reduction or quality adjusted
life years (QALYs). What society is willing to pay for an
additional unit of outcome is an open discussion. Most
of the economic evaluation guidelines refer to this issue
and propose different solutions. In Spain, Sacristan et al.
proposed the amount of 30,000 € per QALY as a value
limit for implementing a new strategy [5]. Other authors
prefer to establish categories defined as feasible, possible
or unfeasible, unless they are necessary to achieve a
high-priority health policy goal.
In Spain, population based screening programs were
established during the 1990s. Some economic evalua-
tions of these programs have been performed. For
instance, in Catalonia, Plans et al. [6] assessed the cost
per woman screened and per cancer detected in 1996
and Beemsterboer et al. [7] used the MISCAN (Mlcrosi-
mulation SCreening ANalysis) model to estimate the
cost-effectiveness of early detection in 1998. In Navarra,
Garuz et al. used decision trees to perform a cost-effec-
tiveness analysis of the Navarra program and a marginal
analysis to assess the inclusion of women 45-49 years
old in the program [8]. Van den Akker-van Marle et al.
used the MISCAN model to evaluate a pilot project in
Navarra and to derive predictions of the long-run costs
and effects of the program [9].
There are two major elements of the cost-effectiveness
of mammography screenings that characterize a specific
screening strategy: 1) the age interval and 2) the periodi-
city of the exams. In Spain, most of population-based
early detection programs target women aged 50-69 and
perform biennial mammograms. Extending the program
to older or younger women has been a matter of inter-
est for health policy-makers. In a previous work we ana-
lyzed the benefit, in terms of mortality reduction and
years of life gained, of different screening strategies in
Catalonia [10] using the Lee and Zelen stochastic mod-
els [11,12]. In the present work our goal was to perform
an economic evaluation of these screening strategies,
taking into account the cost over time of screening
exams and subsequent medical costs, including diagnos-
tic confirmation, initial treatment, follow-up and
advanced care.
Methods
Based on different BC screening recommendations, we
generated 20 possible screening strategies by varying the
periodicity of screening exams and the age intervals of
women screened. We combined annual or biennial
screening with age intervals that started at 40, 45 and
50 years and ended at 69, 70, 74 and 79 years. We also
included the background or non-screening scenario. We
used a probabilistic model to estimate the effect and
costs over time of each screening scenario. We used the
software Mathematica 7.0.1 [13], R 2.11.1 [14] and Stata
11.0 [15] for modeling and data analysis.
The Lee and Zelen stochastic model
Lee and Zelen (LZ) developed a probabilistic model that
predicts mortality as a function of the early detection
modality. The characteristics and assumptions of the LZ
model are described in detail elsewhere [11,12,16-19].
The assumptions of the LZ model are (1) a four-state
p r o g r e s s i v ed i s e a s ei nw h i c has u b j e c tm a yb ei nad i s -
ease-free state (S0), preclinical disease state (Sp: capable
of being diagnosed by a special exam), clinical state (Sc:
diagnosis by symptomatic detection), and a death from
BC state (Sd
bc); (2) age-dependent transitions into the
different states; (3) age-dependent examination sensitiv-
ity; (4) age-dependent sojourn times in each state; and
(5) exam-diagnosed cases have a stage-shift in the direc-
tion of more favorable prognosis relative to the distribu-
tion of stages in symptomatic detection.
The basic LZ model calculates the cumulative prob-
ability of death for the cohort ν exposed to any screen-
ing program after T years of follow-up. Similarly, the
cumulative probability of death for the cohort group
without screening can be calculated. These probabilities
were used to calculate the possible reduction in mortal-
ity from an early detection program after T years of fol-
low-up. We extended the model to estimate incidence
and prevalence. The inputs needed to model the Catalan
data have been published elsewhere [20-22].
Estimation of BC incidence, prevalence and mortality
under different screening scenarios
We estimated the probability of being an incident case
at age u (40 ≤ u < 80) and the probabilities of being a
prevalent case or dying, each year afterwards, condi-
tional to being diagnosed at age u (40 ≤ u < 80). These
values were used to estimate the costs of initial treat-
ment, follow-up and advanced care, respectively.
Incidence
Under a screening scenario, the probability of having a
BC diagnosis at age u, was estimated as the sum of the
probabilities of being detected at the screening exam
and being diagnosed at the interval between two exams.
The model uses q(t), the probability density function of
the sojourn time in pre-clinical state, Sp. A detailed spe-
cification of the incidence estimation can be found in
the Appendix in Additional file 1, sections C.1 and D.1.
Prevalence
Once a woman is diagnosed of BC, she can die from BC
or from other causes. The proportion of women that
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be estimated as:
Prev(u +1 )=I(u) − D(1,u)−
−m−bc(u)(I(u) − 0.5D(1,u))
(1)
where I(u) is the probability of being incident (symp-
tomatic, detected by exam or interval case) in the inter-
val [u,u+1), m
-bc(u) is the central rate of death from
other causes than BC in the same interval, and D(1,u) is
the probability of death from BC during the first year
after diagnosis at age u (Appendix in Additional file 1,
sections C.3 and D.3).
The last summand of equation (1) represents the pro-
portion of incident women that die from other causes in
the age interval [u,u+1). We have assumed indepen-
dence of BC and other causes of death and uniformity
in the distribution of BC deaths in the age interval.
Similarly, for successive years k:
Prev(u + k)=Prev(u + k − 1) − D(k,u)−
− m−bc(u + k)[Prev(u + k − 1) − 0.5D(k,u)]
(2)
Breast cancer mortality
Detailed equations for estimating the probability of
death from BC at different time periods for different
screening scenarios can be found elsewhere [10,12] and
in the Appendix in Additional file 1, sections C.2 and
D.2. Our model has used the BC survival functions from
the US by age and stage for the period 1975-79 [22].
Since this period is prior to the introduction of mam-
mography screening in Catalonia, the survival estimates
were not affected by the lead time bias. Also, the US
functions provided more favorable and realistic survival
estimates than the Catalan ones because adjuvant treat-
ments in Catalonia during the 1980s (pre-screening era)
were less used than in the US.
Measuring the effect of different screening scenarios
For each screening scenario and for the background, we
measured the effect of screening with three outcomes:
1) the number of lives extended (LE); 2) the number of
years of life gained (YL); 3) the number of quality-
adjusted life years gained (QALY). QALYs were esti-
mated applying the weights derived from EuroQol EQ-
5D quality-of-life utility scores that Stout et al. used in
the US [23]. Quality-of-life weights for localized breast
or regional cancer health states were assumed to be 90%
or 75%, respectively, of the values for a healthy woman
of the same 5-year age group, for a period of two years.
Quality-of-life weights for the distant BC state were
assumed to be 60% of the healthy state until her death.
We also considered a loss of QALYs due to the anxiety
derived from the screening mammogram itself (7 days
at 25% of the healthy state) and from a false positive
result (25 days at 25% of the healthy state). Stout et al.
considered the loss of QALYs due to the test results’
anxiety only in their sensitivity analysis.
All the calculations assumed an initial population of
100,000 women at birth. Incidence of BC and mortality
from other causes refer to the cohorts born in the per-
iod 1948-1952. The time horizon for the study was 40-
79 years of age.
Costs’ considerations
Costs can be categorized as direct (either healthcare or
non-healthcare costs), indirect or intangible and each
one of these categories is considered or not depending
on the study’s perspective and on the availability of data.
We have adopted the perspective of the national health
system and considered only the direct healthcare costs.
We have partitioned the estimation of costs into four
parts: screening and diagnosis confirmation, initial treat-
ment, follow-up and advanced care costs. All costs were
valued in 2005 euros and both costs and outcomes have
been discounted at an annual rate of 3%, according to
the economic evaluation guidelines of the Spanish Min-
istry of Heath [24].
Costs of the breast cancer diagnosis under a screening
scenario
The costs of screening mammograms, complementary
tests and administrative expenses were obtained from
the Early Detection Program of IMAS in the city of Bar-
celona. The program covers 42% of women living in
Barcelona. We considered the following costs: screening
mammogram plus administrative costs, 35 €; early recall
mammogram, 23 €; non-invasive complementary tests,
298 €; and invasive tests, 473 €.
To obtain the costs of screening and diagnosis confir-
mation we made the following assumptions:
Part A): While women are screened
￿ All women at risk of BC in the target population
participated in the screening exams and received a
mammogram according to the periodicity and age
interval of each screening scenario.
￿ There were 7% of women that received an addi-
tional mammogram for further assessment or early
recall.
￿ We used the false positive (FP) rates for non-inva-
sive and invasive tests obtained from a Spanish study
that included eight Breast Cancer Early Detection
Programs [25]. We multiplied the FP rates by the
number of women at risk for BC to estimate the
number of women that would receive additional
non-invasive (e.g. ultrasound) or invasive tests (e.g.
biopsy). See further details in Appendix E in Addi-
tional file 1.
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and all the women with BC diagnosed during the
interval would undergo a non-invasive plus an inva-
sive test.
￿ Sensitivity of mammogram was 0.55 for ages 40-45
years, 0.70 for 45-50 years, 0.75 for 50-70 years and
0.80 for > 70 years. These values, used previously by
Lee and Zelen, were derived from the Breast Cancer
Surveillance Consortium database which contains
mammogram screening data and follow-up for
approximately one million US women, dating back
to 1994 [12].
The results obtained when applying the FP rates to
the target population allowed us to estimate the ratio of
negative results/positive results for invasive tests and the
ratio of non-invasive/invasive tests (Table 1, columns 2
and 4). These ratios are different for each of the scenar-
ios because they depend on the number of BC diag-
nosed. Also, these ratios are age-specific and decrease
linearly with age after the sixth year from the start of
the screening.
Part B): After the last screening exam
For screening scenarios where the last screening exam was
performed before the age of 79, we proceed as follows:
￿ Since we do not have FP rate estimates for a popu-
lation without screening, we assumed that the ratio
of benign to malignant biopsy was the same among
screened and non-screened women [26]. We linearly
projected the ratio for non-invasive/invasive tests
during the screening interval up to age 79, for each
screening schedule.
￿ We multiplied the projected ratios by the number
of women diagnosed with BC (true positives)
obtained from the LZ model and we obtained the
number of FP for the invasive tests.
￿ We also linearly projected the ratio of non-inva-
sive/invasive tests during the screening interval, up
to age 79.
￿ We considered that the cumulative rate of invasive
tests in screened women was double this rate in
non-screened women [26].
￿ We multiplied the estimated non-invasive/invasive
ratio by the number of invasive tests to obtain the
number of non-invasive tests.
Costs of the BC diagnosis under the background scenario
For the background scenario, the cost for non-invasive and
invasive complementary tests are the same as for screen-
ing. The cost of mammogram for background was the
same as for early recall screening mammography, 23 €.
To obtain the number of non-invasive and invasive
tests and the FP rates under the background scenario,
we proceeded as described in part B) of the previous
section. However, under the screening scenario the
ratios of negative/positive results for invasive tests and
non-invasive/invasive tests were higher for the six initial
exams and then decreased linearly. Therefore, we
excluded the first six ratios and projected the linear sec-
tion of the series obtained from a population with
annual periodicity of exams in the age interval 50-69
years (Table 1, columns 3 and 5. Also, see Appendix E
in Additional file 1).
Costs of the initial treatment, follow-up and advanced care
Data on costs was obtained from a database that
included 592 women consecutively diagnosed and initi-
ally treated for BC at the IMAS-Hospital del Mar in
Barcelona in the period January 1st, 2000 - December
31, 2003. Cost categories are shown in Table 2. There
were 68 (11.5%) in situ cases which were excluded from
the analysis. The distribution of disease stages at diagno-
sis of invasive tumors was 196 (42%) Stage I, 163 (35%)
Stage II, 74 (16%) Stage III, and 32 (7%) Stage IV.
Initial treatment costs were higher when the BC was
diagnosed in a more advanced stage. The initial treat-
ment lasted approximately one year. The mean costs for
non-metastatic disease were 9,529 € for Stage I, 14,184
€ for Stage II and 16,898 € for Stage III. To the previous
values we added 638 €, the cost of adjuvant tamoxifen
Table 1 Ratios Non-invasive/Invasive tests and Invasive
test -/Invasive test + for a screening scenario with annual
periodicity and exams in the age interval 50 to 69 and
for the background scenario
Age Non-invasive/invasive tests Invasive test -/Invasive test +
Screening Background Screening Background
50 6.92 2.54 2.03 0.57
55 6.19 2.32 0.65 0.5
60 4.21 2.1 0.42 0.42
65 3.79 1.89 0.35 0.35
70 1.67 0.28
75 1.46 0.2
Table 2 Costs’ categories
Cost category Items
In-hospital Length of stay by specialty ward
Ambulatory visits Type of ambulatory visit
Emergency visits
Chemotherapy Drugs
Treatment protocol
Other hospital costs Other drugs
Lab tests
Radiological tests
Radiotherapy Number and type of courses
Hormone therapy Drugs
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diagnosed with a Stage I, II and III. For women diag-
nosed at stage IV, the initial treatment cost was
assumed to be zero and we considered only diagnosis
and advanced care costs.
Follow-up costs for women diagnosed with BC
include ambulatory visits and diagnostic tests that
women receive, starting the year after the BC diagnosis.
Based on the data, we assumed that the cost during the
first year of follow-up was 1,365 € and 530 € for the fol-
lowing four years.
Advanced care cost was obtained using data from the
32 patients diagnosed with metastatic cancer, followed
during five years. Survival at the end of the period was
37.5%. We estimated the cost of advanced care as the
mean of all the direct costs from diagnosis until death
or last follow-up, 28,413 €. Costs for living women after
five years of follow-up did not change the mean
significantly.
Cost-effectiveness analysis
To compare the relative costs and outcomes of the dif-
ferent scenarios, we calculated the incremental cost-
effectiveness ratio (ICER). The ICER is defined as the
ratio of the change in costs to the change in effects of a
specific intervention compared to an alternative. The
ICER indicates the additional cost of obtaining one addi-
tional unit of outcome. We have compared each sce-
nario with the next most effective alternative. Strategies
were classified into three categories: non-dominated,
dominated and extended dominated. A strategy was
considered dominated if it was more expensive and less
effective than another. Extended dominance occurs
when a strategy is improved by mixing with two other
strategies. When costs are plotted on the y axis and out-
comes on the x axis, a dominated strategy lies above and
to the left of the non-dominated strategy.
Once dominated or extended dominated strategies are
excluded, the remaining strategies form the cost-effec-
tiveness frontier,t h eefficient alternatives for which no
alternative policy exists that result in better effects for
lower costs. Usually there is a social threshold, or will-
ingness to pay, that constrains the choice between effi-
cient strategies. Finally, a rational decision maker has to
decide whether or not to move up the efficiency
frontier.
Sensitivity analysis
We performed a sensitivity analysis to study the impact
on our conclusions when some of the inputs were modi-
fied. First, we investigated the effect of increasing all
costs that could be due to, for instance, the introduction
of new drugs. Second, we examined the impact of longer
follow-up times. Third, we changed the ratio of screen-
ing/background non-invasive tests because there is lim-
ited information for estimating this ratio with high
confidence. Fourth, we set the screening participation to
50% in the screening program.F i f t h ,w ed o u b l e dt h e
cost of invasive tests for screen-detected tumors to
account for the difficulty of detecting non-palpable
lesions. All the tested scenarios can be found in Table 3.
For this analysis we present LE and QALYs as measures
of the effect (the results obtained with YL and QALYs
were similar).
Results
Figures 1A, 1B and 1C present the results of the cost-
effectiveness analysis when the effect measures are LE
or YL or QALYs, respectively. The background scenario
was the reference scenario. All the screening alternatives
represented increased effectiveness and costs with
respect to the background scenario.
Table 4 shows the non-dominated or non-extended
dominated alternatives for each effectiveness measure.
The ICER indicates the cost of obtaining an additional
unit of effect when moving from one strategy to the
next.
The detailed results for all the 21 scenarios can be
found in Table A.1 in Additional file 1.
Measuring effectiveness with number of lives extended
(LE)
Figure 1A and Table 4, upper section, present the results
of this analysis. Among the 20 studied screening strategies
and the background scenario, 13 were either dominated or
extended dominated by other strategies. Three of the
seven screening scenarios that should be taken into con-
sideration were biennial and four annual: B50-69, B50-74,
Table 3 Baseline assumptions and ranges tested in the sensitivity analysis
Parameter Baseline model Sensitivity analysis
Initial treatment cost by stage I: 9,960 €, II: 14,616 €, III: 17,329 € 2, 3, 4, 5, 10-fold
Follow-up cost 1,365 € 1st yr., 530 € afterwards 2, 3, 4, 5, 10-fold
Advanced care cost 28,413 € 2, 3, 4, 5, 10-fold
Years of follow-up 5 11, 16, 21
Screening/background noninvasive test 21 , 3
Screening participation 100% 50%
Screening/background cost of invasive tests 12
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Page 5 of 11B50-70, A50-74, A45-74, A40-74 and A40-79. Only one of
them had the last exam at age 79, two scenarios started at
age 40, one at age 45 and four at age 50.
Moving from the background to B50-69, the current
public screening program in Catalonia, represented an
incremental cost of 28,465 € per LE. Moving from B50-
69 to the next alternative, B50-70, represented an incre-
mental cost of 49,184 € per LE. The ICER increased
considerably when moving from biennial strategies to
annual strategies. The last non-dominated strategy, A40-
79 had an ICER of 715,941 €, which should be inter-
preted with caution because we did not account for the
reduction in mortality after age 79.
Measuring effectiveness with years of life gained (YL)
Figure 1B and Table 4, middle section, show the results
of this analysis. Among the selected strategies there were
six scenarios, two of them biennial and four annual: B50-
69, B45-69, A45-69, A40-69, A40-74 and A40-79. Three
of the scenarios, B50-69, A40-74 and A40-79, were also
selected when the effect was measured as LE.
All the selected alternatives, except A40-79, had an
incremental cost lower than 30,000 € per additional YL
and therefore, could be implemented if economic
resources were available. As for the LE analysis, the
results for alternative A40-79 should be interpreted with
caution.
Measuring effectiveness with quality-adjusted life years
(QALYs)
Figure 1C and Table 4, lower section, show the results
of this analysis. Six screening scenarios, three biennial
and three annual, were selected: B50-69, B45-69, B45-
74, A45-69, A40-69 and A40-74. Five of these scenarios
were also selected when the effect was measured as YL
and two of them when the effect was measured as LE.
Compared with the current public screening strategy,
B50-69, all the remaining selected scenarios started the
exams earlier and two of them ended later. All the
selected alternatives had an incremental cost per QALY
lower than 30,000 € and therefore could be considered
for implementation.
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Figure 1 Cost and effectiveness. Cost-effectiveness analysis of different screening strategies: A-Incremental cost (×10
6 €)p e rl i f ee x t e n d e d
(LE); B-per year of life (YL); and C-per quality-adjusted life year (QALY). Empty figures correspond to annual strategies and full figures to
biennial. Screening start age: 40 (big), 45 (medium) and 50 (small). Screening end age: 69 (circle), 70 (diamond), 74 (triangle), and 79 (square).
The line joins the dominant scenarios. D-Cost for all strategies by phase: detection (pink), initial treatment (green), follow-up (blue), and
advanced care (yellow).
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Tables A.2, A.3 and A4 in Additional file 1 show the
selected scenarios after modifying costs, length of fol-
low-up and the ratio of non-invasive tests among
screened and background strategies. Overall, the sensi-
tivity analysis showed that conclusions were not affected
by small or moderate changes in the inputs of the
model.
The input that caused more changes in the selected
screening scenarios was the advanced care cost. When
advanced care cost was three times higher than the
initial value, the background scenario was no longer the
least expensive scenario. The following scenarios: B50-
74, B50-70 and B50-69, in that order, had lower costs
than the background. At the extreme value of advanced
care cost (10-fold) only annual screening strategies were
selected.
When we changed the follow-up time from four to ten
or twenty years, the selected scenarios were the same as
the baseline except for B50-70, which became domi-
nated when the effect was measured in LE. The selected
screening scenarios did not change after modifying the
ratio of non-invasive tests among screened and back-
ground strategies. Assuming that only 50% of the invited
population is screened produced only slight changes in
the selected scenarios but increased the ICER consider-
ably. When costs of invasive tests were doubled for the
screened women there were no changes in the selected
scenarios, there were only slight changes in the ICER
values.
Discussion
Principal findings
This study performed an economic evaluation of differ-
ent BC mammography screening strategies in Catalonia
(Spain), using mathematical models. We assumed the
perspective of the national health system and considered
the direct healthcare costs over time of screening, diag-
nosis, initial treatment, follow-up and advanced care.
Our results show that, based on the incremental cost-
effectiveness ratio (ICER), a reduced number of strate-
gies can be selected for consideration from a set of 20
screening scenarios. Strategies that start at age 50 and
end at age 74 predominate among those selected when
the effectiveness of screening is measured in terms of
the number of lives extended, and strategies that start at
the ages 40 or 45 and end at age 69 predominate when
the effect is measured as YL or QALYs. Independently
of how the effect is measured, the ICER increases con-
siderably when moving from biennial to annual
scenarios.
An interesting result is that, assuming 100% participa-
tion in the studied screening strategies, the background
is always the reference scenario because it has the low-
est cost. But the effectiveness of the background is the
lowest, for all the effect measures. In addition, once the
non dominated scenarios are ordered according the
ICER, always the next alternative is B50-69 that corre-
sponds to the current public screening program in Cata-
lonia. However, in some cases, other alternatives are
more effective at a cost that could be considered imple-
mentable, given the generally accepted reference values.
When the effect is measured as YL or QALY, these
alternatives start the screening at ages younger than 50
years whereas only a few suggest to finish after the age
69.
Sensitivity analysis showed that the results were robust
to moderate changes in costs of treatment or length of
follow-up after initial treatment. Only dramatic increases
of advanced cancer care modified the scenarios selected
in the cost-effectiveness analysis in favor of annual
screening scenarios. We did not perform a sensitivity
analysis of changes in the survival functions as a result
of improvements in mortality and prognosis after a BC
diagnosis. The CISNET groups verified that there was a
Table 4 Cost-effectiveness of mammography screening
strategies in Catalonia (Spain)
Scenario Cost ΔCost Effect ΔEffect ΔC/ΔE (ICER)
(×10
6 €) (×10
6 €)L E ΔLE €/LE
Bg 127.3 0
B 50-69 143.4 16.2 567 567 28,465
B 50-70 144.6 1.1 590 23 49,184
B 50-74 147.0 2.5 640 50 50,188
A 50-74 167.0 20.0 757 117 170,304
A 45-74 182.1 15.1 803 46 330,098
A 40-74 201.5 19.4 837 34 573,062
A 40-79 210.4 8.9 849 12 715,941
YL ΔYL €/YL
Bg 127.3 0
B 50-69 143.4 16.2 4,691 4,691 3,444
B 45-69 151.5 8.1 5,842 1,151 7,015
A 45-69 176.0 24.4 7,917 2,075 11,777
A 40-69 195.4 19.4 9,117 1,200 16,166
A 40-74 201.5 6.2 9,370 253 24,415
A 40-79 210.4 8.9 9,390 20 451,370
QALY ΔQALY €/QALY
Bg 127.3 0
B 50-69 143.4 16.2 3,614 3,614 4,469
B 45-69 151.5 8.1 4,447 833 9,694
B 45-74 153.9 2.4 4,633 186 12,633
A 45-69 176.0 22.1 5,979 1,346 16,411
A 40-69 195.4 19.4 6,756 777 24,975
A 40-74 201.5 6.2 6,987 231 26,720
Incremental cost per effect (LE, YL and QALY) assuming a cohort of 100,000
women at birth. Dominated or extended-dominated strategies are not
included.
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treatments. That means that the benefits of screening
are smaller if treatments are more effective. As Cronin
et al. pointed out, taken to the extreme, if treatment
were completely curative there would be no additional
mortality benefit associated with early detection [27].
Costs of diagnosing and treating breast cancer
Many authors have studied the costs of diagnosing and/
or treating BC [3,4,28-31]. There is high variability in
the methodology, patient characteristics, perspective and
time horizon used. Some authors calculate the net costs
by subtracting the costs of care of age-matched controls
[28,30]. Other authors identify the cancer-associated
costs, which requires someone to decide which costs
should be included. Some studies restrict the analysis to
pre- or post-menopausal status [4] or to screened or
non-screened groups. The objectives of studying costs
also can be very different, from performing a descriptive
study of costs from diagnosis to death [29] to building a
simulation model [31]. Nevertheless some characteristics
are common to most of the studies, for instance, the
acceptance of increasing costs over time of advanced
cancer care, and the substantial weight of hospitalization
costs [28,29,31].
A major challenge is to estimate the costs of advanced
disease. Even though clinical practice guidelines provide
standard treatment for advanced disease, very often
treatments are customized according to the tumor or
the patient’s characteristics and the response to each
treatment line. De Koning et al. [32] and Richards et al.
[33] pioneered the economic evaluation of advanced
cancer care in the early 1990s when screening programs
were spreading and information about their impact was
needed. Recently, Guest et al. estimated the costs of pal-
liative care for BC as £2,482 (at 2000/2001 prices) per
patient [34]. Berkowitz et al. [35] assessed the lifetime
direct costs of treating metastatic disease using the Sta-
tistics Canada’s Population Health Model. On average,
women with metastatic disease were expected to live
three years and to incur direct treatment costs of
approximately $60,000 per case, in 1998 US dollars. In
comparison, patients treated for metastatic BC in our
study had, on average, lower costs, 28,413 €.T h e s ed i f -
ferences may be explained, in part, by financial and
organizational differences in health systems. In 2005,
health care expenditure measured in PPP (Purchasing
Power Parity) per capita was $2,225 in Spain, $3,326 in
Canada and $6,401 in the USA [36].
Campbell et al. reviewed 29 cost-of-illness studies for
B Ci nt h eU S[ 3 7 ] .O ft h e s e ,2 2m e a s u r e do n l yd i r e c t
medical costs and took the health payer perspective.
The estimated lifetime per-patient costs ranged from
$US 20,000 to $US 100,000. The costs of initial and
terminal treatments were greater than follow-up care on
a per-unit-time basis, but follow-up care accounted for
the largest part of lifetime cost due to the relatively long
survival of BC patients. In our study, the estimated cost
over time per patient fluctuated between 26,000 and
35,000 € depending on the intensity of early detection
exams (no screening or annual screening in the 40-79
years of age interval, respectively). When a 3% discount
was applied, cost over time per patient oscillated
between 25,600 and 37,000 € (Table A.1 in Additional
file 1).
The distribution of costs by phase in our study is con-
sistent with the results found in the literature. When
averaging the cost by phase over the different scenarios,
for a cohort of 100,000 women at birth, the highest cost
corresponded to initial treatment (63,083,670 €), fol-
lowed by detection cost (55,353,560 €), advanced cancer
care (33,011,915 €) and the costs of follow-up (3,031,631
€).
Cost-effectiveness of mammography screening
Several authors have studied the cost-effectiveness of
mammography screening using mathematical models
[23,38-41]. Generally, these studies assess the effect of
different screening strategies in relation to no screening.
Some of them include the current guidelines or the
actual screening scenarios among the compared screen-
ing strategies.
Wong et al. studied the cost-effectiveness of mammo-
g r a p h ys c r e e n i n gi nC h i n e s ew o m e ni nH o n gK o n g ,
adopting a societal perspective [39]. They compared
biennial alternatives beginning at ages 40 or 50 and end-
ing at ages 69 or 79, with the results from no screening.
The least costly, non-dominated strategy was screening
from ages 40 to 69 years, with an ICER of $61,600 per
QALY saved or $64,400 per life year saved compared
with no screening. These values were much higher than
ours or other found in the literature. A difference with
our study is that Wong et al. included ductal carcinoma
in situ (DCIS) cases. Lee et al. [41] studied the cost-
effectiveness of mammography screening in Korea using
the model proposed by Lee and Zelen [12]. The effec-
tiveness of mammography screening was defined as the
probability of detecting BC in the preclinical state and
the cost was based on the direct cost of mammography
screening and confirmative tests. They concluded that
biennial mammography screening for women aged at
least 40 years was cost-effective. Ahern et al. assessed
the cost-effectiveness of screening strategies recom-
mended by the National Cancer Institute, the American
Cancer Society (ACS), and the US Prevention Services
T a s kF o r c ei nt h eU S Aa n dc o m p a r e dt h e mw i t ha l t e r -
native strategies, using a microsimulation model. Mam-
mography and clinical breast exams in alternating years
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compared with the guidelines, costing $35,500 per
QALY saved compared with no screening. The ACS
guideline was the most effective and the most expensive,
costing over $680,000 for an added QALY compared
with the above alternative. The authors concluded that
strategies with lower costs and benefits comparable with
those currently recommended should be considered for
implementation in practice and future guidelines.
In Spain, Plans et al., in 1996, compared the direct
health service costs of a round of screening for a pro-
gram that screened women aged 50-64 years with the
resulting estimated cancers detected [6]. They estimated
a cost per women screened of $350 and a cost-effective-
ness ratio of $7,020 per year of life gained. Garuz et al.,
in 1997, performed a cost-effectiveness analysis of a BC
mammography screening program that consisted of a
biennial mammography in all women 50-64 years old
[8]. They used data from the Navarre Screening Pro-
gram, the Guipuzcoa Cancer Registry and the literature.
Costs were estimated using a Markov model and mea-
sured in 1993 ECUs (1 ECU = 1 €)a n dad i s c o u n to f
6%. The cost-effectiveness ratio per avoided death was
115,500 ECUs and 7,300 ECUs per saved life year.
Extending the program to women 45-49 years repre-
sented an incremental cost of 229,000 and 9,400 ECUs,
respectively. We did not analyze the strategy for ages
50-64, but our biennial 50-69 strategy, compared with
the background, resulted in around 28,500 € per avoided
death and 3,500 € per year of life saved. Extending the
program to the 45-49 age group would represent an
incremental cost of 162,000 and 7,000 €, respectively.
O u rv a l u e sa r el o w e rt h a nt h o s er e p o r t e db yG a r u zet
al. This may be explained by differences in cost assess-
ment, in the discount rate and time value of money (6%
and future value in Garuz et al. versus 3% and present
value in ours) and in the age at the last exam, 64 versus
69 years. The non-discounted cost per life saved in the
Garuz et al. study was 38,400 €, a value more similar to
ours.
Beemsterboer et al. [7] using Catalan data on BC mor-
tality, incidence and screening and Dutch data on costs,
obtained cost-effectiveness ratios equivalent to 5,553,
4,387 and 4,321 € per YL (5% discounting) for scenarios
that target women 50-64 years of age with screening
intervals of one, two and three years, respectively. De
Koning et al., in 2000, reported the cost per YL of
screening with biennial mammograms as 2,650 € in
Navarra (ages 45-65), 4,475 € in Catalonia and 7,125 €
in Spain (both for ages 50-69) [42]. Our result, for B50-
69, was 3,555 € per YL, compatible with the Beemster-
boer and de Koning results, even though the costs of
treating BC have increased in the last decade.
Limitations
We have used a very detailed model that allowed us to
thoroughly assess the cost and effectiveness of different
screening scenarios. However, our study has several lim-
itations, among them are the following. Our model
relies on data and assumptions that may be not correct.
When available, we have used Catalan or Spanish data
from population based registries or BC screening pro-
grams. If the input data was not available at the region
or country level, we used data that the CISNET had pre-
pared for BC mortality modeling research groups in the
USA [43]. Finally, there were some inputs that Lee and
Zelen had obtained from published randomized clinical
trials and observational studies. In a previous publica-
tion, we performed a sensitivity analysis to assess the
effect of departures from the modeling assumptions on
the effectiveness of early detection [10] and we con-
cluded that the model was robust.
We have not obtained confidence intervals of the
model outputs. Our model is probabilistic because it
works with the probability density functions of the dif-
ferent inputs related to the natural history or detection
of BC. It is also an analytic model that consists of a set
of equations describing BC mortality over time. There is
uncertainty associated with the model inputs and there
is also uncertainty associated with the model structure.
It is complex and computationally intensive to obtain
the variance of the model estimates. Instead, we have
carried out a sensitivity analysis to explore how changes
in the input parameters affect the results.
With respect to the outcome measures, we have
included LE as a measure of effect together with YLG
and QALYs. We want to highlight that the standard and
internationally recognized measure to compare different
health interventions and measure their effectiveness is
the QALY [44]. Although it can be interesting to esti-
mate the amount of LE, this measure is less robust as
a no u t c o m em e a s u r ea n dc a n n o tb er e c o m m e n d e da s
the basis for population-based policy decisions.
With respect to costs, we have several considerations.
a) Costs were obtained from a single public hospital in
Barcelona, which may not be representative of the hos-
pitals in the region. However, we believe that the costs
of diagnosing and treating BC in the hospitals of the
Catalan public health system are not remarkably differ-
ent. b) Advanced care costs were obtained from a small
sample of metastatic BC patients at diagnosis. About
one third of them were still alive after five years. Includ-
ing living patients in the calculations may have underes-
timated the average cost of treating advanced disease.
Excluding living patients from the analysis would have
produced a biased sample. More adequate methods,
based on the Kaplan-Meier sample average estimate
Carles et al. BMC Cancer 2011, 11:192
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not have all the necessary information to apply them,
such as the costs of treatment over time on a monthly
basis. c) Innovative treatments for advanced BC that
currently may represent an improvement in survival or
q u a l i t yo fl i f ea sw e l la sa ni n c r e a s ei nc o s tw e r en o t
available in the 2000-2003 time period. Despite these
issues, sensitivity analyses showed that the results only
changed when costs varied dramatically. d) We
restricted the study to direct healthcare costs and the
perspective of the national health system because the
sources of indirect costs and the methods used to esti-
mate them are heterogeneous, thus the estimates have
high variability depending on the approach adopted.
Reviewing some works that analyze the differences in
the total costs (direct and indirect) for cancer patients
in Spain, we found that indirect costs can represent
from 20% to 70% of the total costs [46,47]. Obviously,
the results that we present could have been very differ-
ent if indirect costs had been considered.
The decision of implementing a specific alternative is
influenced by the budget assigned to the screening pro-
gram and also by the amount that society is willing to
pay for each effectiveness unit. Since the number of LE
or mortality reduction is not a standard effectiveness
measure in economic assessments, is not easy to find
reference values for comparison.
T h e r ei ss c a r c ei n f o r m a t i o ni nt h el i t e r a t u r ea b o u t
rates of false positives for invasive and non-invasive
tests to diagnose BC in a non-screened population.
Again, the sensitivity analysis showed that the selected
scenarios were robust to changes in the assumptions.
Our study did not take into account either overdiag-
nosis of BC as a consequence of screening or DCIS. The
impact of overdiagnosis would be to increase costs and
decrease quality of life. Strategies with a higher number
of screening exams (annual) would have a higher incre-
mental cost per additional effect unit and, therefore,
would end up being dominated by less intensive screen-
ing strategies (biennial). We have not accounted for
overdiagnosis because there is high variability in over-
diagnosis estimates. When we studied overdiagnosis in
our region, we obtained a high association between
exposure to screening and an increase in incidence,
beyond what was expected by the advance of diagnosis,
but the precision of the overdiagnosis estimate was low
[ 4 8 ] .W ew o u l dl i k et oh a v eam o r ep r e c i s ee s t i m a t eo f
overdiagnosis before including it in the model.
In our model, DCIS cases were not included. The
researchers that developed the probabilistic model that
we have used considered that available information on
the natural history of in situ disease was insufficient to
include in situ tumors in the model [11]. When
observing the results of the CISNET groups in the USA,
there does not seem to be a pattern between the screen-
ing benefits (in terms of mortality reduction) produced
by the models and whether or not they modeled in situ
disease [27]. Nevertheless, including DCIS would
increase the costs of treatment and decrease quality of
life for the DCIS tumors that would not progress, simi-
larly to overdiagnosis. We plan to incorporate both,
DCIS and overdiagnosis, in future models.
Conclusions
We have studied the cost-effectiveness of several BC
screening scenarios and have selected a reduced number
of them for consideration by researchers, decision
makers and policy planners. Mathematical models have
been useful to assess the impacts and costs of BC
screening interventions, accounting for the population
and epidemiological data of a specific geographical area.
Additional material
Additional file 1: Appendix. The file contains further details of the
model for the estimation of BC incidence, prevalence, mortality, false
positive tests, and additional tables.
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